An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
NCT ID: NCT05728502
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2400 participants
OBSERVATIONAL
2023-04-25
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and death.
The drug vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). The sGC enzyme helps to regulate the heart and blood circulation. Vericiguat is already available in China and other countries for doctors to prescribe to people with heart failure. Vericiguat has already been studied in previous clinical studies. However, the data from these studies were restricted by inclusion and exclusion criteria. Therefore, this real-world study will collect important data from real-world setting in China.
The main purpose of this study is to collect more data on how well vericiguat works compared with current SOC in Chinese people with HFrEF under everyday conditions.
Working well means that the treatment can prevent the following from happening:
* death due to heart and circulatory events,
* a hospital stay due to heart conditions (failure).
In addition, the study team will gather more information about how safe the study drug vericiguat is for Chinese people with HFrEF. To do this, the researchers will collect all medical problems the participants have during the study. These medical problems are also known as "adverse events" and may or may not be related to the study treatment.
Subsequently, the study team will compare the data between participants who received the study drug vericiguat and those who received SOC. The SOC is the currently appropriate treatment in accordance with scientific evidence and agreed upon in collaboration between medical experts for HFrEF.
The participants will take vericiguat as prescribed by their doctors during routine practice according to the approved product information. For the vericiguat group, data will be collected at routine visits, which are not mandated by this study. The data for the comparison (SOC group) will come from a database called China Heart Failure Center. These data will be collected retrospectively for a comparable period of time.
The following data from the study participants will be documented during visits that take place in routine practice every 3 months:
* underlying and concomitant diseases,
* prior medication,
* laboratory parameters,
* vital signs such as blood pressure, heart rate,
* results of cardiac exams (e.g. echocardiography),
* information about how and in which amount vericiguat is usually given to patients.
The participants will be treated with vericiguat and followed up to 12 months or until they leave the study, whatever comes first.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vericiguat arm
Chinese adult patients with Heart Failure with Reduced Ejection Fraction (HFrEF) who are prescribed vericiguat under routine treatment conditions. Data will be prospectively collected.
Vericiguat (Verquvo, BAY1021189)
Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
external control arm
Chinese adult HFrEF patients who received SoC treatment will be collected from China Heart Failure Center registry database. This control arm will be retrospectively collected from the patients in the database in the same period, from FPFV to LPFV of the vericiguat arm, and matched by propensity score based on baseline characteristics.
Standard of Care (SoC)
Dosage at the discretion of the treating physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vericiguat (Verquvo, BAY1021189)
Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
Standard of Care (SoC)
Dosage at the discretion of the treating physician.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female and male patients ≥ 18 years of age who are naïve to vericiguat treatment
* Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization)
* Decision to initiate treatment with vericiguat as per the local approved label
* Signed informed consent
control arm
* Aged 18 or over at baseline
* Only patients receiving SoC for chronic heart failure (no history of receiving vericiguat prior to the index date)
* Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization)
Exclusion Criteria
* Participation in other investigational program with interventions outside of routine clinical practice
* Contra-indications according to the local marketing authorization label
control arm
* Patients who have started therapy with vericiguat for chronic heart failure at baseline
* Contra-indications according to the vericiguat local marketing authorization label
* Patients participating in an interventional study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese Registries
Multiple Locations, Many Locations, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for access to information about Bayer's transparency standards and Bayer studies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22323
Identifier Type: -
Identifier Source: org_study_id